Fireside Chat: Beyond the Needle: Oral, Intranasal & AI-Driven Drug Delivery Platforms - RANI THERAPEUTICS HOLDINGS INC

Financial Performance:

• Ended June with $53 million in cash and securities following a $20 million registered direct offering led by a sovereign wealth fund.
• Executed a strategic partnership with Chugai with a headline value up to $1.1 billion, including a $10 million upfront, $18 million in tech transfer, $57 million in development milestones, and $100 million in sales milestones, plus 5% digital royalties.
• PEG-Bio collaboration announced; Rani Therapeutics does not currently carry significant debt after retiring obligations from prior raises.
• Cost of Goods Sold (COGS) for the device is projected to be low single digits per pill due to non-electronic materials (plastic, sugar, effervescent agent), scaling with volume.
• Cash runway has been conservatively updated to extend through 2027, excluding potential upside from Chugai milestone payments.

Guidance and Future Outlook:

• Phase 1b repeat-dose obesity study for RT-114 (PG-102 via Rani Pill) is scheduled to begin by end of year, with data expected in 2027.
• ACH-001 (Stelara oral) data modeling suggests 84% relative bioavailability requiring 12 pills annually.
• Company anticipates reporting at least one new Chugai milestone in 2027.
• Management aims to launch oral GLP-1/GLP-2 therapies with once-weekly dosing, avoiding the frequent dosing schedules of current oral small molecule competitors.
• Long-term goal is to become the premier delivery partner for diverse modalities (antibodies, peptides, oligos, siRNAs) across obesity, rare diseases, and other indications.

Business Segments and Product Lines:

• Core platform: "Rani Pill," an ingestible autoinjector that dissolves in the stomach and deploys a dissolving needle in the small intestine via effervescent inflation.
• Obesity Program: RT-114, an oral delivery of Progen's PG-102 (GLP-1/GLP-2 dual agonist), demonstrated >150% bioavailability relative to subcutaneous injection in Phase 1.
• Rare Disease: Collaboration with Chugai for hemophilia (Factor VIII, 300 kDa) and potential options for five additional targets; Phase 1 data for Factor VIII and Stelara (114 kDa) previously shown.
• Metabolic Portfolio: Partnership with PEG-Bio to oral deliver various obesity molecules, including pentagonists and triagonists.
• Manufacturing: Scalable production model relying on simple inputs; no electronics or complex machinery in the device itself.

Market and Competitive Landscape:

• Differentiation: Achieves bioavailability equivalent or superior to subcutaneous injection, solving the "holy grail" of oral biologics where competitors typically achieve <1% bioavailability.
• Competitive Advantage: Unlike oral semaglutide (daily dosing, high API ingestion), RT-114 aims for weekly dosing with significantly lower drug product ingestion and a better tolerability profile.
• Market Validation: Demonstrated efficacy on large molecules (monoclonal antibodies, 300 kDa Factor VIII) which other oral delivery technologies cannot currently address.
• Patient Preference: Oral administration is preferred by patients despite side effects of current oral competitors; Rani targets tolerability and weight retention.

Risks and Challenges:

• Skepticism regarding bioavailability consistency in larger, repeat-dose studies.
• Concerns over manufacturing scalability and cost of goods compared to standard pens or small molecules.
• Historical skepticism due to the "science fiction" nature of the device and previous early programs that did not advance rapidly.
• Regulatory pathways for ingestible devices require rigorous safety data regarding the dissolution mechanism and potential for device retention or injury (though no device-related adverse events observed in 250+ oral administrations).

Management Commentary and Tone:

• Tone is highly confident and optimistic, characterizing the technology as a definitive solution to decades of failed oral biologic attempts.
• CEO Talat Imran emphasized the platform's versatility across all biologic modalities and the strategic value of the Chugai partnership.
• CFO Nick Myos (note: transcript refers to "Nick Myosis/MyosIS") provided transparent, conservative financial guidance, distinguishing actual cash on hand from potential milestone payments.
• Management dismissed the "150% vs 100%" bioavailability debate as secondary to the ability to deliver large molecules orally.

Analyst Questions and Answers:

• Q: Why oral GLP-1 when oral small molecules exist? A: Weekly dosing, lower API ingestion, reduced side effects (nausea/vomiting at half the rate of competitors), and preservation of lean body mass.
• Q: Chugai deal structure and future milestones? A: 50/50 cost share, IP ownership split, market rights split (Rani: US/EU/UK/Aus/Canada; Chugai: Asia); upcoming milestones tied to platform advancement expected in 2027.
• Q: Funding runway and dilution? A: Cash extended through 2027; clinical trials are efficient and partially funded by partners (Chugai covers 100% of their program costs), reducing need for repeated dilution.
• Q: Why were early programs discontinued? A: Market novelty caused initial investor hesitation; the Chugai deal (2 years of diligence) validated the platform and secured capital.
• Q: Specifics on RT-114 expansion cohort? A: Adding 15 volunteers to characterize PK relationship for Phase 1b dosing; aiming for higher serum concentrations at lower doses.

Other Key Points:

• The device mechanism is non-electronic, inspired by an effervescent tablet reaction to inflate a balloon that aligns a micro-syringe.
• No device-related adverse events reported across 250+ oral administrations in clinical trials; no injection site reactions (ISRs).
• Rani Therapeutics (Ticker: RANI) is currently in its fourth Phase 1 study.
• Management highlighted the potential for the platform to enable oral delivery of 300 kDa molecules like Factor VIII, a size class currently impossible for other oral technologies.